Tirzepatide 2mg — Vial Spec, Reconstitution Math & COA

Specification Overview: What Is a 2mg Tirzepatide Research Vial?

A 2mg tirzepatide research vial contains precisely 2.0 milligrams of high-purity, lyophilized synthetic peptide cake. Chemically classified as an engineered 39-amino-acid peptide derivative, tirzepatide features a structure derived from native glucose-dependent insulinotropic polypeptide (GIP) sequence elements conjugated to a C20 fatty diacid diacyl chain via a linker. This specific structural modification enables extended binding affinity and albumin interaction during in vitro and animal model evaluation.

In laboratory research settings, a 2mg fill size represents an optimal unit mass for exploratory pilot assays, single-phase cellular kinetic studies, or initial micro-dosing protocols where larger vial quantities (such as 5mg, 10mg, or 15mg) would introduce unwanted excess solution or subject the reconstituted matrix to repeated freeze-thaw cycles. Researchers select 2mg formats to maximize reagent efficiency while maintaining strict volumetric control over target concentrations.

PX1 Catalog Availability & Format Guidance

PX1 Research maintains rigorous manufacturing and fill-finish schedules to support preclinical research facilities across the USA. Depending on active production runs and laboratory demand, specific mass options—including 2mg, 5mg, 10mg, and specialized dual-target formulations like glp2-t—are dynamically updated within our central inventory.

If a discrete 2mg single-vial unit is out of stock during a specific procurement window, investigators are encouraged to evaluate standard catalog equivalents or review our full catalog at all peptides to identify alternative mass options or related metabolic research peptides. All fill sizes, regardless of mass, adhere to identical analytical purity standards, endotoxin limits, and sterile lyophilization parameters.

Dual GIP and GLP-1 Receptor Agonism in Preclinical Research

Tirzepatide is structured to act as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. In vitro receptor binding assays demonstrate that tirzepatide exhibits potency equivalent to native GIP at the GIP receptor, while displaying a biased, lower-potency interaction at the GLP-1 receptor compared to native GLP-1.

Preclinical studies suggest that simultaneous activation of these two distinct incretin pathways yields synergistic downstream metabolic signal transduction. In rodent models of metabolic dysregulation, dual agonism has been observed to modulate cyclic adenosine monophosphate (cAMP) generation, alter cell-surface receptor internalisation kinetics, and influence central neuronal pathways regulating energy homeostasis to a greater extent than selective mono-agonists.

Reconstitution Math & Volumetric Concentration Standards

Accurate volumetric reconstitution of a 2mg tirzepatide vial requires precise matching of solvent volume to target working concentration. Laboratory personnel typically utilize sterile bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline depending on cell line sensitivity and assay duration.

To achieve target working solutions from a 2.0 mg lyophilized mass, apply the following volumetric calculations:

1.0 mL Diluent Addition: Yields a final concentration of 2.0 mg/mL (2.0 µg/µL or 2000 µg/mL). This high-density working solution is optimal for micro-pipetting very small mass increments or concentrated stock solution storage.

2.0 mL Diluent Addition: Yields a final concentration of 1.0 mg/mL (1.0 µg/µL or 1000 µg/mL). This standard 1:1 concentration ratio simplifies volumetric calculations during high-throughput microplate loading.

3.0 mL Diluent Addition: Yields a final concentration of 0.67 mg/mL (0.67 µg/µL or 667 µg/mL). This lower concentration range is useful when pipetting larger volumes to minimize margin-of-error during delicate in vitro dilutions.

To rapidly verify concentration calculations across various solvent volumes and custom vial masses, researchers can utilize the PX1 reconstitution calculator tool prior to solvent introduction.

Aliquot Planning & Volumetric Pipetting Protocols

Lyophilized peptides exhibit maximum chemical stability when maintained in sealed, low-moisture environments. However, once reconstituted into aqueous media, tirzepatide becomes subject to potential peptide chain hydrolysis, oxidation, and surface adsorption. To preserve biological activity across extended study timelines, primary stock solutions should be divided into single-use aliquots immediately following complete dissolution.

Using sterile, low-binding polypropylene micro-centrifuge tubes, aliquot the reconstituted 2mg solution into predefined volumes based on daily assay requirements (e.g., 50 µL or 100 µL fractions). Gently swirl the vial during reconstitution—never vortex vigorously, as mechanical shear stress can disrupt secondary structural folding and promote peptide aggregation. Store working aliquots at sub-zero temperatures to eliminate repeated freeze-thaw cycles that destabilize the peptide sequence.

Analytical Quality Assurance: Lot-Matched COA Protocols

Every production lot of tirzepatide manufactured for PX1 Research undergoes strict analytical verification prior to laboratory release. High-Performance Liquid Chromatography (HPLC) is conducted to confirm chemical purity thresholds exceeding 99.0%, ensuring that truncated sequences, synthesis side-products, and residual reagents are systematically eliminated.

Mass Spectrometry (MS) analysis confirms exact molecular mass against theoretical sequence weight, validating structural identity. Furthermore, Limulus Amebocyte Lysate (LAL) testing is performed on every fill lot to guarantee endotoxin levels remain strictly under <0.05 EU/mg. Investigators can access and download batch-specific analytical documentation directly through our centralized COA database.

Lyophilized and Reconstituted Stability Profiles

Thermal management is critical to maintaining peptide integrity throughout transit and bench storage. In its lyophilized state, a 2mg tirzepatide vial remains stable at room temperature (15°C to 25°C) for short-term transit, but long-term laboratory preservation requires storage at -20°C or -80°C in a desiccated, dark environment.

Following reconstitution with bacteriostatic water, the solution should be kept refrigerated at 2°C to 8°C and evaluated within 28 days. If reconstituted in non-preserved sterile 0.9% sodium chloride or sterile water for injection, working solutions must be utilized immediately or frozen at -80°C to prevent microbial proliferation and structural degradation over extended timelines.

Selecting Optimal Fill Sizes: 2mg vs. 5mg vs. High-Yield Vials

Determining whether a 2mg vial or a larger format is required depends directly on experimental design, assay duration, and subject group sizes. A 2mg format is ideal for exploratory pilot assays, initial binding affinity screens, or low-volume micro-dosing protocols where avoiding excess waste and long-term solution decay is a primary constraint.

Conversely, multi-week animal model studies or high-throughput cell culture assays requiring continuous daily dosing benefit from high-capacity formats such as 5mg, 10mg, or 15mg vials. Larger unit sizes lower the cost-per-milligram baseline and streamline batch consistency. Principal investigators managing large-scale laboratory requirements can explore bulk procurement options through the PX1 wholesale portal.

Comparative Profile: In Vitro Incretin Mimetics

When evaluating metabolic regulatory compounds in preclinical research, tirzepatide is frequently analyzed alongside other key incretin mimetics to contrast mono-, dual-, and triple-agonist mechanism dynamics. Understanding these structural and functional variations assists researchers in selecting the appropriate reference compound for specific bioassays.

In comparative cellular assays, the selective GLP-1 receptor mono-agonist semaglutide provides a robust single-pathway baseline for GLP-1 receptor activation. In contrast, tirzepatide integrates dual GIP/GLP-1 signaling, demonstrating enhanced downstream glycogen synthesis activation in primary hepatocyte cultures. For multi-target research, the triple agonist retatrutide—which incorporates glucagon receptor activation alongside GIP and GLP-1 targets—presents an expanded mechanism for investigating multi-receptor metabolic synergy. Researchers can explore detailed receptor kinetics across our broader research library.

Laboratory Safety, Handling, and Compliance Standards

Tirzepatide is supplied strictly as a synthesized research chemical intended exclusively for in vitro laboratory research and preclinical animal experimentation. It is not formulated, labeled, or certified for human or veterinary administration, medical treatment, or clinical diagnostic procedures.

Laboratory personnel handling tirzepatide should adhere to standard Biosafety Level 1 (BSL-1) or Level 2 (BSL-2) protocols depending on host cell lines or model organisms. Personal protective equipment (PPE), including nitrile gloves, lab coats, and safety eyewear, must be worn during reconstitutions and pipetting procedures. All unused materials and micro-vials should be disposed of in accordance with regional hazardous biological and chemical waste regulations.